CSL889

Product Information

Scientific name: CSL889 (Human hemopexin)
Brand name: Ν/Α
RESPONSIBLE: CSL Behring

Clinical Trial/Study Information

Trial Name: Rhemedy
Code: NCT06699849
Phase: 2/3
Eligible patient diagnosis: Adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC)
No. of Patients enrolled: 260 [anticipated] (Last update: 23/07/2025)
Study Sites: 9 Sites per country

Completion date: April 2028 (anticipated)
Scope of the Study / Aim: Assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD, and to evaluate the safety and tolerability of CSL889 in study participants.

Regulatory Information

Status: Not Authorised

Additional notable points:

• EMA: Orphan drug designation (2020)
• FDA: Orphan drug designation (2020)
• MHRA: N/A